Views: 0 Author: Site Editor Publish Time: 2025-12-23 Origin: Site
In the highly competitive world of pharmaceutical development, the success of a blockbuster drug often hinges on the quality of its molecular precursors. 2-Fluoro-3-nitrobenzoic acid (CAS No. 317-46-4) is one such "silent hero."
This compound serves as a primary building block for the synthesis of Dabrafenib, a life-saving medication for patients with BRAF-mutant cancers. The strategic placement of the fluorine atom at the 2-position and the nitro group at the 3-position provides the necessary electronics and geometry for the drug to bind effectively to its biological target. Beyond oncology, it is a versatile reagent in the development of antimicrobial and anti-inflammatory agents.
The market for 2-Fluoro-3-nitrobenzoic acid is driven by the global expansion of targeted cancer therapies:
As Dabrafenib continues to be a standard-of-care treatment, the demand for ultra-high-purity intermediates like CAS 317-46-4 remains consistently high.
The presence of the fluorine atom makes this intermediate attractive for synthesizing advanced quinolone derivatives, which are crucial for treating antibiotic-resistant infections.
Its unique regiochemistry allows researchers to perform nucleophilic aromatic substitution on the fluorine or reduction of the nitro group to an amine, opening doors to thousands of bioactive variations.
Synthesizing 2-Fluoro-3-nitrobenzoic acid is a precision exercise in aromatic chemistry. Industrially, it is critical because:
Standard nitration of fluorobenzoic acid often yields a mixture of isomers. Advanced manufacturing requires proprietary routes (such as directed ortho-lithiation or selective oxidation of nitrotoluene precursors) to ensure the 2,3-substitution pattern is achieved with minimal contamination from the 2,5- or 2,6-isomers.
The conversion of methyl groups to carboxylic acids in the presence of sensitive nitro and fluoro groups requires optimized catalytic systems to avoid degradation or byproduct formation.
As an intermediate for oncology drugs, this product must meet "Medical Grade" specifications. Even trace impurities can interfere with the high-yield coupling reactions required for final API production.
When choosing a supplier for CAS No. 317-46-4, pharmaceutical procurement teams focus on:
The supplier must provide detailed H-NMR and F-NMR data to confirm the absence of positional isomers.
For oncology intermediates, residual catalysts (like chromium or manganese from oxidation steps) must be strictly limited to the parts-per-million (ppm) level.
Full support for DMF (Drug Master File) filings and comprehensive SDS/Technical Data Sheets are non-negotiable for regulated pharmaceutical manufacturing.
The following global leaders are recognized for their ability to produce this complex intermediate with the precision required for pharmaceutical use:
With over 30 years of excellence in the synthesis of pharmaceutical intermediates, EASTFINE is a preferred global partner for 2-Fluoro-3-nitrobenzoic acid. We offer:
We utilize proprietary low-temperature lithiation and carbonylation techniques to ensure that our product is free from difficult-to-separate isomers, guaranteeing purity of ≥ 99.0%.
Our production lines follow strict cGMP-aligned protocols, ensuring that the material is ready for direct use in the synthesis of Dabrafenib and other high-value drugs.
From grams for initial discovery to metric tons for commercial manufacturing, EASTFINE provides a stable and secure supply chain.
We provide comprehensive documentation packages, including impurity profiles and certificates of analysis (COA) for every batch.
As a premier provider of research chemicals, they supply high-purity 317-46-4 for global R&D and pilot-scale development. They are trusted for their extensive analytical verification and distribution network.
A leading Indian specialist in drug impurity standards and pharmaceutical intermediates. Simson Pharma provides high-quality building blocks and custom synthesis services for the global pharmaceutical market.
Based in the United States, Synthonix specializes in medicinal chemistry building blocks. They are known for providing high-precision fluorinated and nitrated aromatics used specifically in drug discovery.
A rapidly growing Indian manufacturer specializing in high-end intermediates. They focus on providing cost-effective, high-purity solutions for the synthesis of complex pharmaceutical molecules.
In the synthesis of oncology medications, there is no room for error. EASTFINE understands that the purity of your intermediate is the foundation of your final drug’s efficacy.
Choosing EASTFINE means:
Our high-precision synthesis ensures you get the 2,3-isomer every time, protecting your downstream yields.
With our complete documentation and ISO certification, we help you clear regulatory hurdles faster.
Our team of scientists is available to support your process optimization, ensuring a seamless transition from bench to bulk.
2-Fluoro-3-nitrobenzoic acid (CAS No. 317-46-4) is a cornerstone of modern oncology and medicinal chemistry. Its role in the synthesis of life-saving drugs like Dabrafenib makes it one of the most important building blocks in the industry today. Partner with EASTFINE to secure a high-purity, reliable supply that meets the demanding standards of the pharmaceutical world.
简体中文
